This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Emergent BioSolutions Management Presents At JPMorgan SMid Cap Conference (Transcript)

To give everybody and I see some familiar faces here, so I apologize if I go over old news but for those of you who don't know Emergent, we have the only FDA licensed anthrax vaccine, which is BioThrax. We're organized into two divisions, BioDefense, which primarily is focused on the anthrax infectious disease. As well as BioSciences, and that's oncology and autoimmune. And you see those are the three disease areas that we're focused on.

We have eight clinical-stage candidates at this point in time. And we've had nine years of profitability and look forward to completing this year as a profitable biotech as well.

This gives you a very quick overview of the clinical candidates that we have today and it's a mixture of BioD and BioDefense. I'm not going to go through each and every one. That could take up to 20 minutes by itself. I will highlight a couple of them a little bit further into the presentation. You can see we've got a couple in Phase 3, couple in Phase 2, couple in Phase 1. We've also got a number of pre-clinical candidates, which we will not be talking about.

So, to get into the BioDefense division and give you a little bit of background on BioThrax. As I said, it's the only FDA-licensed anthrax vaccine. It's been in over 2.5 million individuals to date. It's got a safety profile, which is well established and quite enviable in the vaccine field. We now have four-year dating on this product and one might say, why is that so special.

Number one, BioThrax is primarily purchased by the government today for stockpiling purposes. So the longer the shelf life, the better. And at four-year dating, we have the longest shelf life of any vaccine that's licensed today.

Today's regimen is five doses over 18 months with an annual boost. We're working on improving that and I'll talk to that in just a moment. We manufacture this at a single manufacturing location. Our current capacity is about 7 million to 9 million doses per year. We're increasing that manufacturing capacity. We've got a new building and I'll take you through some of the details of that in just a moment.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs